Aldosterone and aldosterone antagonism in cardiovascular disease: Focus on eplerenone (Inspra)

Heart Disease

Volumn 5, Issue 2, 2003, Pages 102-118

  Stier Jr , Charles T ^a   Koenig, Seth ^a   Lee, Davis Y ^a   Chawla, Mohit ^a   Frishman, William H ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Aldosterone; Cardiovascular disease; Eplerenone; Spironolactone

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BUMETANIDE; CAPTOPRIL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; FUROSEMIDE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ATHEROSCLEROSIS; BREAST TENDERNESS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SELECTIVITY; ELECTROLYTE DISTURBANCE; FIBRINOLYSIS; GYNECOMASTIA; HEART ARRHYTHMIA; HEART DEATH; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HORMONE INHIBITION; HUMAN; HYPERKALEMIA; HYPERTENSION; IMPOTENCE; MENSTRUAL IRREGULARITY; MORTALITY; PRESSORECEPTOR; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STEROIDOGENESIS; VASCULAR ENDOTHELIUM; VASCULAR FIBROSIS;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ARRHYTHMIA; BAROREFLEX; DEATH, SUDDEN, CARDIAC; ENDOMYOCARDIAL FIBROSIS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; RENIN-ANGIOTENSIN SYSTEM;

EID: 0038523886     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.HDX.0000061698.20666.aa     Document Type: Review

References (136)

1. Simpson SA, Tait JF, Bush IE. Secretion of a salt-retaining hormone by the mammalian adrenal cortex. Lancet. 1952;263:226-228.
2. Christ M, Meyer C, Sippel K, et al. Rapid aldosterone signaling in vascular smooth muscle cells: involvement of phopholipase C, diacylglycerol and protein kinase Cα. Biochem Biophys Res Commun. 1995; 213:123-129.
3. Schneider M, Ulsenheimer A, Christ M, et al. Nongenomic effects of aldosterone on intracellular calcium in porcine endothelial cells. Am J Physiol. 1997;272:E616-E620.
4. Stier CT Jr., Chander PN, Rocha R, et al. Nonepithelial effects of aldosterone. Curr Opin Endocrinol Diabetes. 1998;5(3):211-216.
5. Takeda Y, Miyamori I, Yoneda T, et al. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab. 1996;81:2797-2800.
6. Silvestre JS, Robert V, Delcayre C, et al. Myocardial production of aldosterone and corticosterone in the rat. Physiologic regulation. J Biol Chem. 1998;273:4883-4891.
7. Pitt B, Zannad F, Remme W, et al., for the RALES Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
8. Zannad F. Aldosterone and heart failure. Eur Heart J. 1995;16(Suppl N):98-102.
9. Struthers AD. Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J. 1995;16(Suppl N):103-106.
10. RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol. 1996;78:902-907.
11. Struthers AD. Aldosterone: cardiovascular assault. Am Heart J. 2002; 144:S2-S7.
12. Funder JW. New biology of aldosterone and experimental studies on the selective aldosterone blocker eplerenone. Am Heart J. 2002;144: S8-S11.
13. Delyani JA. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int. 2000;57:1408-1411.
14. Delyani JA, Rocha R, Cook CS, et al. Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc Drug Rev. 2001;19:185-200.
15. Chiou CY, Williams GH, Kifor I. Study of the rat adrenal reninangiotensin system at a cellular level. J Clin Invest. 1995;96:1375-1381.
16. Funder JW, Pearce PT, Smith R, et al. Mineralocorticoid action target tissue specificity is enzyme, not receptor, mediated. Science. 1988;242: 583-585.
17. Lombes M, Kenouch S, Souque A, et al. The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11βhydroxysteroid dehydrogenase. Endocrinology. 1994;135:834-840.
18. Pearce P, Funder JW. High affinity aldosterone binding sites (type I receptors) in rat heart. Clin Exp Pharmacol Physiol. 1987;14:859-866.
19. Lombes M, Alfaidy N, Eugene E, et al. Prerequisite for cardiac aldosterone action. Mineralcorticoid receptor and 11β-hydroxysteroid dehydrogenase in the human heart. Circulation. 1995;92:175-182.
20. Cohn JN. Current therapy of the failing heart. Circulation. 1988;78: 1099-1107.
21. Tan LB, Jalil JE, Pick R, et al. Cardiac myocyte necrosis induced by angiotensin II. Circ Res. 1991;69:1185-1195.
22. Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 1990;82:1730-1736.
23. Swedberg K, Eneroth P, Kjekshus J, et al, for the CONSENSUS Trial Study Group. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (Follow-up of the CONSENSUS trial). Am J Cardiol 1990;66:40D-45D.
24. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577-585.
25. Vantrimpont P, Rouleau JL, Ciampi A, et al. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) study. Eur Heart J. 1998;19:1552-1563.
26. Vaughan DE, Lamas GA, Pfeffer MA. Role of left ventricular dysfunction in selective neurohumoral activation in the recovery phase of anterior wall acute myocardial infarction. Am J Cardiol. 1990;66:529-532.
27. Ambrosius WT, Bloem LJ, Zhou L, et al. Genetic variants in the epithelial sodium channel in relation to aldosterone and potassium excretion and risk for hypertension. Hypertension. 1999;34:631-637.
28. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
29. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310.
30. Biollaz J, Brunner HR, Gavras I, et al. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol. 1982;4:966-72.
31. Staessen J, Lijnen P, Fagard R, et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981;91:457-465.
32. Zannad F. Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment. Am J Cardiol. 1993;71:34A-39A.
33. Urata H, Nishimura H, Ganten D. Mechanisms of angiotensin II formation in humans. Eur Heart J 1995;16:(Suppl N) 79-85.
34. LeJemtel TH, Sonnenblick EH, Frishman WH. Diagnosis and management of heart failure. In: Fuster V, Alexander RW, O'Rourke RA. Hurst's The Heart. 10th ed. New York: McGraw-Hill, 2001:687-724.
35. Lind L, Lithell H, Wide L, et al. Metabolic cardiovascular risk factors and the renin-aldosterone system in essential hypertension. J Hum Hypertension. 1992;6:27-29.
36. Goodfriend TL, Egan B, Stepniakowski K, et al. Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans. Hypertension. 1995;25:30-36.
37. Muller J. Spironolactone in the management of congestive heart failure: a review. Clin Therap. 1986;9:63-76.
38. Settel E. Further experience with spironolactone-hydrochlorothiazide (Aldactazide-A) in the long-term treatment of refractory cardiac edema. Am J Geriat Soc. 1965;13:655-662.
39. Smith AGE. Spironolactone in the long-term management of patients with congestive heart failure. Curr Med Res Opin. 1980;7:131-136.
40. Yasky J, Ledesma GA, Tutera A, et al. The treatment of non-digitalized congestive heart failure patients with a fixed-dose combination of furosemide and spironolactone. Pharmatherapeutica. 1986;4:480-485.
41. Yasky J, Ledesma GA, Tutera A, et al. A fixed-dose combination of furosemide and spironolactone in digitalized congestive heart failure patients. Pharmatherapeutica. 1986;4:473-479.
42. Lee DC, Johnson RA, Bingham JB, et al. Heart failure in outpatients: a randomized trial of digoxin versus placebo. New Engl J Med. 1982;306: 699-705.
43. Gerlag PG, Van Meyel JJ. High-dose furosemide in the treatment of refractory congestive heart failure. Arch Intern Med. 1988;148:286-291.
44. Cogan MG. Angiotensin II. a powerful controller of sodium transport in the early proximal tubule. Hypertension. 1990;15:451-458.
45. Dahlstrom U, Karlsson E. Captopril and spironolactone therapy for refractory congestive heart failure. Am J Cardiol. 1993;71:29A-33A.
46. Van Vliet A, Donker AJ, Nauta J, et al. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol. 1993;71:21A-28A.
47. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689-1697.
48. Bauersachs J, Heck M, Fraccarollo D, et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction. Role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol. 2002;39:351-358.
49. Pitt B, Williams G, Remme W, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther. 2001;15:79-87.
50. Farquharson CAJ, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/Angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594-597.
51. Rajagopalan S, Pitt B. Aldosterone antagonists in the treatment of hypertension and target organ damage. Curr Hypertens Rep. 2001;3: 240-248.
52. Rajagopalan S, Duquaine D, Pitt B, et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation. 2002;105: 2212-2216.
53. Vaughan DE, Lamas GA, Pfeffer MA. Role of left ventricular dysfunction in selective neurohumoral activation in the recovery phase of anterior wall acute myocardial infarction. Am J Cardiol. 1990;66:529-532.
54. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest. 1995;95:995-1001.
55. Brown NJ, Kim KS, Chen YQ, et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab. 2000;85:336-344.
56. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol. 2002;283:H1802-H1810.
57. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med. 1992;120:893-901.
58. Rossi GP, DiBello V, Ganzaroli C, et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension. 2002;40:23-27.
59. Stier CT Jr, Chander PN, Gutstein WH, et al. Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect. Am J Hypertens. 1991;4:680-687.
60. Selye H, Hall CE, Rowley EM. Malignant hypertension produced by treatment with desoxycorticosterone acetate and sodium chloride. Can M A J. 1943;49:88-92.
61. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol. 1993;71:12A-16A.
62. Funder J. Mineralocorticoids and cardiac fibrosis: the decade in review. Clin Exp Pharmacol Physiol. 2001;28:1002-1006.
63. Bonvalet JP, Alfaidy N, Lombes M, et al. Aldosterone: intracellular receptors in human heart. Eur Heart J. 1995;16(Supplement N):92-97.
64. Lombes M, Oblin ME, Gasc JM, et al. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res. 1992;71:503-510.
65. Zhou G, Kandala JC, Weber KT, et al. Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts. Mol Cell Biochem. 1996;154:171-178.
66. Kohler PJ, Bertschin S, Woodtli T, Resink T, Erne P. Does aldosteroneinduced cardiac fibrosis involve direct effects on cardiac fibroblasts? J Vasc Res. 1996;33:315-326.
67. Weber KT, Sun Y, Guarda E, et al. Myocardial fibrosis in hypertensive heart disease: an overview of potential regulatory mechanisms. Eur Heart J. 1995;16(Suppl C):24-28.
68. Sato A, Funder JW. High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinology. 1996;137:4145-4153.
69. Hempel A, Maasch C, Heintze U, et al. High glucose concentrations increase endothelial cell permeability via activation of protein kinase Cα. Circ Res. 1997;81:363-371.
70. Young MJ, Funder JW. Mineralocorticoids, salt, hypertension: effects on the heart. Steroids. 1996;61:233-235.
71. Young MJ, Funder JW. The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis. Am J Physiol. 1996;271:E883-E888.
72. Weber KT, Sun Y, Campbell SE, et al. Vascular remodeling and mineralocorticoids. J Endocrinol Invest. 1995;18:533-539.
73. Keeley FW, Elmoselhi A, Leenen FH. Enalapril suppresses normal accumulation of elastin and collagen in cardiovascular tissues of growing rats. Am J Physiol. 1992;262:H1013-H1021.
74. Benetos A, Lacolley P, Safar ME. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol. 1997;17:1152-1156.
75. Rocha R, Stier CT Jr, Williams GH, et al. Aldosterone: A mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000;141: 3871-3878.
76. Ward MR, Kanellakis P, Funder J. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation. 2001;104:467-472.
77. Suzuki G, Morita H, Mishima T, et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation. 2002;106:2967-2972.
78. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res. 1997;35:30-34.
79. Delyani JA, Robinson EL, Rudolph AE. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol. 2001; 50:H647-H654.
80. Silvestre JS, Heymes C, Delcayre C, et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation. 1999;99:2694-2701.
81. Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342:1778-85.
82. Weber KT, Brilla CG. Myocardial fibrosis and the renin-angiotensinaldosterone system. J Cardiovasc Pharmacol. 1992;20(Suppl 1):S48-S54.
83. Conn JW. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955;45:3-17.
84. Tucker RM, Labarthe DR. Frequency of surgical treatment for hypertension in adults at the Mayo Clinic from 1973 through 1975. Mayo Clin Proc. 1977;52:549-555.
85. Gomez-Sanchez CE. Primary aldosteronism and its variants. Cardiovasc Res. 1998;37:8-13.
86. Rocha R, Stier CT Jr. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab. 2001;12:308-314.
87. Rossi GP, Sacchetto A, Pavan E, et al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation. 1997; 95:1471-1478.
88. Rossi GP, Sacchetto A, Visentin P, et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension. 1996;27:1039-1045.
89. Denolle T, Chatellier G, Julien J, et al. Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, aldosterone-producing adenoma, and pheochromocytoma. Am J Hypertens. 1993;6:907-913.
90. Schunkert H, Hense HW, Muscholl M, et al. Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. Heart. 1997;77:24-31.
91. Sato A, Suzuki Y, Saruta T. Effects of spironolactone and angiotensinconverting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res. 1999;22:17-22.
92. Pitt B, Reichek N, Metscher B, et al., for the Eplerenone 017 Investigators. Efficacy and safety of eplerenone, enalapril, and eplerenone/enalapril combination therapy in patients with left ventricular hypertrophy [abstract]. Am J Hypertens. 2002;15:23A-24A.
93. Schneider M, Ulsenheimer A, Christ M, et al. Nongenomic effects of aldosterone on intracellular calcium in porcine endothelial cells. Am J Physiol. 1997;272(4 Part 1):E616-E620.
94. Gomez-Sanchez EP, Fort CM, Gomez-Sanchez CE. Intracerebroventricular infusion of RU28318 blocks aldosterone-salt hypertension. Am J Physiol. 1990;258(3 Part 1):E482-E484.
95. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol. 1995;269: E657-E662.
96. Berecek KH, Stocker M, Gross F. Changes in renal vascular reactivity at various stages of deoxycorticosterone hypertension in rats. Circ Res. 1980;46:619-624.
97. Schiffrin EL, Franks DJ, Gutkowska J. Effect of aldosterone on vascular angiotensin II receptors in the rat. Can J Physiol Pharmacol. 1985;63:1522-1527.
98. Ullian ME, Schelling JR, Linas SL. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension. 1992;20:67-73.
99. Bruner CA. Vascular responsiveness in rats resistant to aldosterone-salt hypertension. Hypertension. 1992;20:59-66.
100. Weber MA, Purdy RE. Catecholamine-mediated constrictor effects of aldosterone on vascular smooth muscle. Life Sci. 1982;30:2009-2017.
101. Wang W, McClaim JM, Zucker IH. Aldosterone reduces baroreceptor discharge in the dog. Hypertension. 1992;19:270-277.
102. Hatakeyama H, Miyamori I, Fujita T, et al. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem. 1994;269:24316-24320.
103. Gehr TWB, Sica DA, Frishman WH. Diuretic therapy in cardiovascular disease. In Frishman WH, Sonnenblick EH, Sica D (eds): Cardiovascular Pharmaco-therapeutics. 2nd ed. New York:McGraw-Hill, 2003; 157-176.
104. Weinberger MH, Roniker B, Krause SL, et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15:709-716.
105. Krum H, Nolly H, Workman D, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension. 2002;40:117-123.
106. Burgess E, Lacourciere Y, Puopolo A, et al. The selective aldosterone blocker eplerenone is safe and efficacious for the long-term treatment of mild-to-moderate hypertension [abstract]. Am J Hypertens. 2002; 15(Suppl):57A.
107. White WB, Carr AA, Oigman W, et al. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinic BP in patients with systolic hypertension. Am J Cardiol. (In Press).
108. Weber MA. Clinical implications of aldosterone blockade. Am Heart J. 2002;144:S12-S18.
109. Weinberger MH, MacDonald T, Conlin PR, et al., the Eplerenone 019 Investigators. Comparison of eplerenone and losartan in patients with low-renin hypertension (abst). Am J Hypertens. 2002;15(4 pt 2):24A.
110. Weir MR, Saunders E. Pharmacologic management of systemic hypertension in blacks. Am J Cardiol. 1988;61:46H-52H.
111. Weir MR. Impact of age, race, and obesity on hypertensive mechanisms and therapy. Am J Med. 1991;90(suppl 5A):3S-14S.
112. Drayer JI, Weber MA. Monotherapy of essential hypertension with a converting-enzyme inhibitor. Hypertension. 1983;5:III108-113.
113. Flack JM, Oparil S, Pratt JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black patients and white patients. J Am Coll Cardiol. In Press.
114. Gibbs CR, Beevers DG, Lip GY. The management of hypertensive disease in black patients. QJM. 1999;92:187-192.
115. Epstein M, Buckalew V, Jr, Martinez F, et al., for the Eplerenone 021 Investigators. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria [abstract]. Am J Hypertens. 2002;15:24A.
116. White WB, Lewin AJ, Nestel R, et al. Comparison of selective aldosterone blockade versus calcium antagonism on blood pressure, vascular compliance, and microalbuminuria in systolic hypertension in older people [abstract]. Am J Hypertens. 2002;15(Suppl):23A.
117. Arora RB, Somani P. Ectopic arrhythmia provoking action of aldosterone. Life Sci. 1962;5:215-218.
118. Guideri G. Death in ventricular fibrillation induced by isoproterenol in DOCA-salt pretreated rats preceded by changes in myocardial electrolytes. Life Sci. 1983;33:1353-1362.
119. Barr CS, Lang CC, Hanson J, et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1995;76: 1259-1265.
120. Dyckner T. Relation of cardiovascular disease to potassium and magnesium deficiencies. Am J Cardiol. 1990;65:44K-46K.
121. Horton R, Biglieri EG. Effect of aldosterone on the metabolism of magnesium. Endocrinology. 1962;22:1187-1192.
122. Turlapaty PD, Altura BM. Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death from ischemic heart disease. Science. 1989;208:198-200.
123. Miyagi H, Yasue H, Okumura K, et al. Effect of magnesium on anginal attack induced by hyperventilation in patients with variant angina. Circulation. 1989;79:597-602.
124. Dyckner T, Wester PO, Widman L. Effects of spironolactone on serum and muscle electrolytes in patients on long-term diuretic therapy for congestive heart failure and/or arterial hypertension. Eur J Clin Pharmacol. 1986;30:535-540.
125. Eichhorn EJ, Tandon PK, Di Bianco R. Clinical and prognostic significance of serum magnesium concentration in patients with severe congestive heart failure: The PROMISE study. J Am Coll Cardiol. 1993;21:634-640.
126. Malik M, for the Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Circulation. 1996;93:1043-1065.
127. Panina G, Khot UN, Nunziata E, et al. Role of spectral measures of heart rate variability as markers of disease progression in patients with chronic heart failure not treated with angiotensin-converting enzyme inhibitors. Am Heart J. 1996;131:153-157.
128. Yee KM, Struthers AD. Aldosterone blunts the baroreflex response in man. Clin Sci. 1998;95:687-692.
129. Guo GB, Abboud FM. Angiotensin II attenuates baroreflex control of heart rate and sympathetic activity. Am J Physiol. 1984;246:H80-H89.
130. Osterziel KJ, Dietz R, Schmid W, et al. ACE inhibition improves vagal reactivity in patients with heart failure. Am Heart J. 1990;120:1120-1129.
131. Marakas SA, Kyriakidis MK, Vourlioti AN, et al. Acute effect of captopril administration on baroreflex sensitivity in patients with acute myocardial infarction. Eur Heart J. 1995;16:914-921.
132. Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension. 1994;24:571-575.
133. Zucker IH, Wang W, Brandle M, et al. Neural regulation of sympathetic nerve activity in heart failure. Prog Cardiovasc Dis. 1995;37: 397-414.
134. Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol. 2001;37:1800-1807.
135. de Gasparo M, Joss U, Ramjoue HP, et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther. 1987;240:650-656.
136. Jeunemaitre X, Chatellier G, Kreft-Jais C, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60: 820-825.